Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Meric-Bernstam, F; Tannir, NM; Iliopoulos, O; Lee, RJ; Telli, ML; Fan, AC; DeMichele, A; Haas, NB; Patel, MR; Harding, JJ; Voss, MH; Owonikoko, TK; Carthon, B; Srinivasan, R; Bendell, JC; Jenkins, Y; Whiting, SH; Orford, K; Bennett, MK; Bauer, TM

Meric-Bernstam, F (通讯作者),UT MD Anderson Canc Ctr, Dept Invest Canc Therapeut, 1400 Holcombe Blvd,Unit 455, Houston, TX 77030 USA.

CLINICAL CANCER RESEARCH, 2022; 28 (8): 1540